IRIS

Furmecyclox

CASRN 60568-05-0 | DTXSID2024119

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (8 pp, 94 K) Last Updated:
Not assessed under the IRIS Program.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (8 pp, 94 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (8 pp, 94 K) Last Updated: 09/07/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • Dose-related increased incidence of neoplastic nodules, carcinomas and combined neoplasic nodules/carcinomas in the liver of female rats and increased incidence of liver nodules and carcinomas and urothelial tumors of the bladder in male rats.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (8 pp, 94 K)

Oral Slope Factor: 3.0 x 10-2 per mg/kg-day
Drinking Water Unit Risk: 8.6 x 10-7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Combined liver nodules and carcinomas (BASF Wyandotte, 1984a)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (8 pp, 94 K)

Not Assessed under the IRIS Program.


Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.